STX-241

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameSTX-241
Drug Alias NameSTX-241PFL-241
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR C797S inhibitors
TargetsEGFR 19delEGFR C797S
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesScorpion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPierre Fabre Médicament ProductionCatalent San Diego IncScorpion Therapeutics Inc +[5] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A